JP2019099571A5 - - Google Patents

Download PDF

Info

Publication number
JP2019099571A5
JP2019099571A5 JP2018223465A JP2018223465A JP2019099571A5 JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018223465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019099571A (ja
JP7461104B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019099571A publication Critical patent/JP2019099571A/ja
Publication of JP2019099571A5 publication Critical patent/JP2019099571A5/ja
Priority to JP2024045935A priority Critical patent/JP7767492B2/ja
Application granted granted Critical
Publication of JP7461104B2 publication Critical patent/JP7461104B2/ja
Priority to JP2025182210A priority patent/JP2026016628A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018223465A 2017-11-29 2018-11-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 Active JP7461104B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024045935A JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A JP2026016628A (ja) 2017-11-29 2025-10-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017228661 2017-11-29
JP2017228661 2017-11-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024045935A Division JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2019099571A JP2019099571A (ja) 2019-06-24
JP2019099571A5 true JP2019099571A5 (https=) 2022-01-06
JP7461104B2 JP7461104B2 (ja) 2024-04-03

Family

ID=66975925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018223465A Active JP7461104B2 (ja) 2017-11-29 2018-11-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Country Status (1)

Country Link
JP (3) JP7461104B2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110618208A (zh) * 2019-09-10 2019-12-27 威海迪素制药有限公司 一种(s)-(+)-3-羟基四氢呋喃对映异构体含量检测方法
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
US12037339B2 (en) * 2020-07-20 2024-07-16 Eccogene Inc. Substituted imidazoles as GLP-1 receptor agonists
EP4211133A4 (en) * 2020-09-07 2024-11-27 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CN116368140A (zh) * 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023016546A1 (en) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4522131A1 (en) * 2022-05-11 2025-03-19 Eli Lilly and Company Glp1 tablet compositions
PE20260136A1 (es) * 2022-05-11 2026-01-21 Lilly Co Eli Composiciones farmaceuticas de glp1
CN120712085A (zh) * 2022-12-13 2025-09-26 伊莱利利公司 Orforglipron用于治疗患有2型糖尿病(t2d)、肥胖症或超重伴至少一种体重相关合并症的个体的剂量方案
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
CN120659776A (zh) * 2022-12-19 2025-09-16 伊莱利利公司 Glp1 ra及其中间体的制备方法
EP4652167A1 (en) * 2023-01-17 2025-11-26 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025002250A1 (zh) * 2023-06-29 2025-01-02 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
IL325536A (en) * 2023-06-30 2026-02-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound containing a multi-fused ring structure
TW202508571A (zh) * 2023-07-28 2025-03-01 大陸商上海翰森生物醫藥科技有限公司 一種苯并含氮雜環類衍生物調節劑、其製備方法和應用
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
CN121941685A (zh) 2023-11-10 2026-04-28 重庆药友制药有限责任公司 一种glp-1r激动剂化合物及其应用
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
TW202542146A (zh) * 2023-12-05 2025-11-01 大陸商信達生物科技有限公司 靶向glp-1受體的化合物以及其用途
WO2025124357A1 (zh) * 2023-12-14 2025-06-19 广东众生睿创生物科技有限公司 一种杂环glp-1受体激动剂及其应用
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025261454A1 (zh) * 2024-06-19 2025-12-26 上海翰森生物医药科技有限公司 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2026001866A1 (zh) * 2024-06-24 2026-01-02 联邦生物科技(珠海横琴)有限公司 一种glp-1受体激动剂及其应用
WO2026012449A1 (zh) * 2024-07-12 2026-01-15 联邦生物科技(珠海横琴)有限公司 一种具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026032183A1 (en) * 2024-08-05 2026-02-12 Rongchang Pharmaceuticals, Ltd. Nitrogen-containing fused ring compound, pharmaceutical composition and use thereof
WO2026052129A1 (zh) * 2024-09-09 2026-03-12 中国科学院上海药物研究所 多环杂芳烃类glp-1受体激动剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
EP2591675A1 (en) 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroaryl amide derivatives
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
JP6314335B2 (ja) 2013-02-06 2018-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
EP2993174A1 (en) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Similar Documents

Publication Publication Date Title
JP2019099571A5 (https=)
JP2021502066A5 (https=)
JP2019030304A5 (https=)
JP2020042034A5 (https=)
JP2022028828A5 (https=)
JP2022025124A5 (https=)
JP2021185136A5 (https=)
JP2021169491A5 (https=)
JP2021518389A5 (https=)
JP2019031552A5 (https=)
JP2018154848A5 (https=)
JP2020534795A5 (https=)
JP2020007340A5 (https=)
JP2020040981A5 (https=)
JP2021503478A5 (https=)
JP2019068846A5 (https=)
JP2021500894A5 (https=)
JP2021038271A5 (https=)
JP2017214405A5 (https=)
JP2016196495A5 (https=)
JPWO2020148954A5 (https=)
JP2018135352A5 (https=)
JP2021524864A5 (https=)
JP2021502339A5 (https=)
JP2018111825A5 (https=)